 |
 |
SmithKline Beecham is interested in consumer feedback regarding their new dopamine agonist, Requip. If you have constructive suggestions regarding what you like/don't like/suggest regarding the product, its packaging, consumer educational materials, programs, incentives, pricing, etc, please email us directly (APDA [log in to unmask]) so we can pass this on to SmithKline when we meet with them in a few weeks. Please do not press "Reply" to respond We do not want to clutter the list with everyone's suggestions to the company. We look forward to hearing from you. Thanks! APDA Young Parkinson's Center APDA [log in to unmask]